Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Kalydeco Articles

Vertex shoots up 60% on positive trial results for Kalydeco and VX-661

22 April 2013

Vertex receives first two Breakthrough Therapy Designations from US FDA

10 January 2013

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco

20 December 2012

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

3 December 2012

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis

29 October 2012

FDA warns on possible cataract risk with Vertex' Kalydeco

31 August 2012

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30 July 2012

Vertex tumbles despite good final data on combo cystic fibrosis therapy

1 July 2012

Vertex slumps as firm revises Kalydeco data

30 May 2012

EMA recommends approval of Vertex' CF drug Kalydeco

28 May 2012

FDA approves combo diabetes drug Jentadueto and Kalydeco

1 February 2012

Vertex plans for Kalydeco launch

9 January 2012

Vertex updates on US and EU Kalydeco filings; to get new CEO

16 December 2011

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis

6 November 2011

Vertex files for US priority review and approval of Kalydeco for cystic fibrosis

20 October 2011

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS